Viyash Scientific Limited

rs,

iences February 11, 2025 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. National Stock Exchange of India Limited Listing Departmen

18.7%

global pharmaceuticals platform with end to end capabilities . Our Q3FY25 revenues saw a growth of 18.7% Year-on-Year (“YoY”) to Rs 3,908 mn with strong double digit growth in both Formulations and API. W

Rs 3,908

m with end to end capabilities . Our Q3FY25 revenues saw a growth of 18.7% Year-on-Year (“YoY”) to Rs 3,908 mn with strong double digit growth in both Formulations and API. When aggregated for the first nine

14.0 %

and API. When aggregated for the first nine months the overall revenue growth of the company is at 14.0 % YoY. Our gross margins have continued to trend upwards as we register the benefits of pricing, pro

INR 494

cost improvement have further helped in the improvement in profitability. Our EBITDA (pre-esop) of INR 494 Mn represents a 63.8% growth YoY for the quarter, while the first nine months EBITDA (pre-esop) at

63.8%

rther helped in the improvement in profitability. Our EBITDA (pre-esop) of INR 494 Mn represents a 63.8% growth YoY for the quarter, while the first nine months EBITDA (pre-esop) at Rs 1424 Mn showed a g

Rs 1424

Mn represents a 63.8% growth YoY for the quarter, while the first nine months EBITDA (pre-esop) at Rs 1424 Mn showed a growth of 116.5% YoY. The global formulations business grew at 19.8% YoY for the quarter

116.5%

oY for the quarter, while the first nine months EBITDA (pre-esop) at Rs 1424 Mn showed a growth of 116.5% YoY. The global formulations business grew at 19.8% YoY for the quarter, driven by volume growth i

19.8%

A (pre-esop) at Rs 1424 Mn showed a growth of 116.5% YoY. The global formulations business grew at 19.8% YoY for the quarter, driven by volume growth in Europe, better product mix in Turkey, and field ex

17.7 %

I business witnessed strong interest in the deworming segment, and registered a YOY revenue growth 17.7 % for the quarter. Our facilities in Turkey and Mahad received approvals of global agencies, thereby

19%

approvals. Viyash Life Sciences continues to deliver strong performance , with a revenue growth of 19% YoY for Q3 FY25 and EBITDA ( pre Esop ) growth of 68% YoY for this quarter, while accelerating the

68%

strong performance , with a revenue growth of 19% YoY for Q3 FY25 and EBITDA ( pre Esop ) growth of 68% YoY for this quarter, while accelerating the rate of new filings and new product launches. We are

“Emerging Markets: : Turkey sales growth is driven by recovery of volume losses and selective price increases India: Steady growth YoY owing to Project Udaan (field expansion) .”

“+ 3.0% Gross Margin and +3.4% EBITA Margin Improvement YoY in Q3 FY25: •Formulations: Timely price increase in Turkey along with closely monitoring the product mix in Europe, focusing on high- margin products API: Cost and operational excellence initiatives under Project Pragati led to an expansion in margins Operating expenses increase primarily due to higher inflation in Turkey and marketing initiatives aimed at supporting sales growth in Turkey and Europe.”

“Viyash: Business Update Viyash: Q3 FY25 – Continued strong performance on revenue, profitability and cashflows Revenues Adj.”

“EBITDA is adjusted for ESOP costs, accelerated vesting of warrants, call option charge and merger expenses Source: Viyash Life Sciences website published Investor Presentation 13 Viyash: 9M FY25 – Robust YTD performance Revenues Adj.”

“Capacity-412KL USFDA for Advanced Intermediates Viyash: Financial performance All values in ₹ Mn Particulars Q3 FY25 Q3 FY24 Grw YoY % Q2 FY25 Grw QoQ % 9M YTD FY25 9M YTD FY242 Grw YoY % Revenue from Operations 3,839 3,226 19.0% 3,632 5.7% 10,872 9,896 9.9% Material Consumption (1,751) (1,443) 21.4% (1,624) 7.8% (4,956) (4,721) 5.0% Gross Profit % Employee Benefit Expenses Other Operating Expenses Foreign Exchange Gain / (Loss) Adj.”

“9MFY24 based on management accounts that have not been subject to limited review by auditors Source: Viyash Life Sciences website published Investor Presentation 18 Merger Update Q3FY25: Combined business performance Q3 FY25 (For the quarter) Revenue (INR Mn) EBITDA1 (INR Mn) SeQuent Combined YoY Growth % (Combined) 3,839 3,908 7,747 18.8% 685 494 1,179 66.3% EBITDA Margin % 17.8% 12.6% 15.2% +435bps Net Debt to LTM EBITDA 0.4x 2.1x 1.2x Notes: 1.”

“This accounting amortization will continue till FY27 Exceptional Items include cost of accelerated vesting for share warrants, call option charge and merger expenses (Viyash) PAT adjusted for Amortization of acquisition intangibles (net of tax) and Exceptional Items 1.”

Key Notes

2

SeQuent

1

SeQuent

Q3FY25 Performance Update Q3 FY25 Performance Highlights – Sustained Revenue and Profit Growth Strengthening Our Position All values in ₹ Mn Revenues EBITDA (Pre ESOP) EBITDA margin PBT ₹3,908 Million 18.7% YoY ₹494 Million 63.8% YoY 12.6% 348 bps YoY ₹81 Million 444% YoY 7 9M FY25 - Robust Revenue and EBITDA Growth, Fueling Momentum for a Successful Year All values in ₹ Mn Revenues EBITDA (Pre ESOP) EBITDA margin PBT ₹11,497 Million ₹1,424 Million 14.0% YoY 116.5% YoY 12.4% 590 bps YoY ₹280 Million 149% YoY 8 SeQuent : Q3 FY25: Revenue Performance – by geography All values in ₹ Mn Revenue Distribution Formulations Europe Emerging Markets India APIs Other Sales Global Sales One Offs # Adjustment* - Ind AS 29* Q3 FY25 Q2 FY25 QnQ Gr% 2,836 1,335 1,160 341 773 22 3,631 6.1% 0.0% 17.8% -9.9% 5.0% 3.4% 5.8% 3,008 1,334 1,366 308 812 23 3,843 13 43 3,686 65 3,908 QnQ Gr% (In cc) 8.9% 3.0% 21.1% -9.9% 4.5% 3.4% 7.9% 8.0% Q3 FY24 YoY Gr% YoY Gr% (In cc) 19.2% 4.6% 40.8% 10.7% 16.1% -46.8% 17.

Key Notes

+ 3.0% Gross Margin and +3.4% EBITA Margin Improvement YoY in Q3 FY25: •Formulations: Timely price increase in Turkey along with closely monitoring the product mix in Europe, focusing on high- margin products API: Cost and operational excellence initiatives under Project Pragati led to an expansion in margins Operating expenses increase primarily due to higher inflation in Turkey and marketing initiatives aimed at supporting sales growth in Turkey and Europe. Increase in ESOP is on account of additional shares allotted in Sep’24. *Taxes: In Q3’FY’24 there was one-time significant tax benefit accounted in Turkey due to change in Hyperinflation Accounting methodology as prescribed by Turkey to regulatory authorities which exceptional tax benefit in FY’24 which was pertaining to FY’21, FY’22 and Fy’23 lead # PAT Growth: Excluding above exception one time Tax benefit in Q3 FY’24 on like-to- like basis there is strong PAT growth as well in Q3 FY’25 and 9M FY’25. Viyash: Business Update Viya

Key Notes

ESOP cost, Exceptional items and amortization of acquisition intangibles are non-cash or non-recurring accounting items that pertain to prior period events: - Exceptional Items include cost of accelerated vesting for share warrants, call option charge and merger expenses - Amortization of acquisition intangibles in Viyash is on account of intangibles created during acquisitions done in FY22. This accounting amortization will continue till FY27 Exceptional Items include cost of accelerated vesting for share warrants, call option charge and merger expenses (Viyash) PAT adjusted for Amortization of acquisition intangibles (net of tax) and Exceptional Items 1. 2. Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers 25 For details, feel free to contact: Yoshita Vora Company Secretary Abhishek Singhal Investor Relations Consultant +91 22 4111 4777 abhishek@arunya.co.in investorrelations@sequent.in Registered Office: 301/A, ‘Dosti Pinnacle', Plot No. E7, Roa